EGFR (ErbB) Signaling Pathways in Pancreatic Cancer Pathogenesis

  • Monique Williams
  • Gwen Lomberk
  • Raul Urrutia
Reference work entry


The epidermal growth factor receptor (EGFR/ErbB) signaling axis influences the development, maintenance, and disease of tissues throughout the body. Effects have been demonstrated on normal cell proliferation, migration, differentiation, adhesion, and apoptosis in pancreas as well as heart, muscle, nervous system, and a wide variety of organ epithelia. In addition, alterations in the epidermal growth factor (EGF) pathway, including overexpression of the ErbB family of receptor tyrosine kinases, mutations in downstream mediators (e.g., Ras), as well as aberrant signaling, are present in the vast majority of pancreatic and other solid tissue tumors. The importance of the ErbB signaling axis to cancer is illustrated by the number of articles and reviews published on this topic to date (>20,000 and >3000, respectively). In line with the importance of ErbB signaling to cancer, several anticancer therapies have been developed targeting various parts of the ErbB signaling axis and are currently in use, with more undergoing intense development and investigation. Presently, the NIH currently cites an extensive list of clinical studies of ErbB signaling in cancer.


ErbB Epidermal growth factor EGF EGFR Signaling Pancreatic cancer Therapy Molecular imaging 



Work in the authors’ laboratories is supported by NIH DK52913 (to RU), NIH CA178627 (to GL), ChiRhoClin, Research Institute (to RU and GL), as well as the Mayo Clinic SPORE in Pancreatic Cancer (P50 CA102701).


  1. 1.
    Reynolds VH, Boehm FH, Cohen S. Enhancement of chemical carcinogenesis by an epidermal growth factor. Surg Forum. 1965;16:108–9.PubMedGoogle Scholar
  2. 2.
    Debray C, Reversat R. Antiulcer extracts taken from the gastrointestinal mucosa and the urine. Sem Hop. 1950;26(50):2419–29.PubMedGoogle Scholar
  3. 3.
    Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci. 2008;65(10):1566–84.CrossRefGoogle Scholar
  4. 4.
    Kritzik MR, et al. Expression of ErbB receptors during pancreatic islet development and regrowth. J Endocrinol. 2000;165(1):67–77.CrossRefGoogle Scholar
  5. 5.
    Means A, et al. Overexpression of heparin-binding EGF-like growth factor in mouse pancreas results in fibrosis and epithelial metaplasia. Gastroenterology. 2003;124(4):1020–36.CrossRefGoogle Scholar
  6. 6.
    Burtness B. Her signaling in pancreatic cancer. Expert Opin Biol Ther. 2007;7(6):823–9.CrossRefGoogle Scholar
  7. 7.
    Pryczynicz A, et al. Expression of EGF and EGFR strongly correlates with metastasis of pancreatic ductal carcinoma. Anticancer Res. 2008;28(2B):1399–404.PubMedGoogle Scholar
  8. 8.
    Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp Cell Res. 2003;284(1):2–13.CrossRefGoogle Scholar
  9. 9.
    Blobel CP, Carpenter G, Freeman M. The role of protease activity in ErbB biology. Exp Cell Res. 2009;315(4):671–82.CrossRefGoogle Scholar
  10. 10.
    Swindle CS, et al. Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. J Cell Biol. 2001;154(2):459–68.CrossRefGoogle Scholar
  11. 11.
    Tzahar E, et al. Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. EMBO J. 1998;17(20):5948–63.CrossRefGoogle Scholar
  12. 12.
    Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006;12(18):5268–72.CrossRefGoogle Scholar
  13. 13.
    Jones RB, et al. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature. 2006;439(7073):168–74.CrossRefGoogle Scholar
  14. 14.
    Carpenter G. ErbB-4: mechanism of action and biology. Exp Cell Res. 2003;284(1):66–77.CrossRefGoogle Scholar
  15. 15.
    Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res. 2003;284(1):54–65.CrossRefGoogle Scholar
  16. 16.
    Massie C, Mills IG. The developing role of receptors and adaptors. Nat Rev Cancer. 2006;6(5):403–9.CrossRefGoogle Scholar
  17. 17.
    Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2(12):897–909.CrossRefGoogle Scholar
  18. 18.
    Wymann MP, Schneiter R. Lipid signalling in disease. Nat Rev Mol Cell Biol. 2008;9(2):162–76.CrossRefGoogle Scholar
  19. 19.
    Carpenter CL, et al. Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. J Biol Chem. 1993;268(13):9478–83.PubMedGoogle Scholar
  20. 20.
    Sjolander A, et al. Association of p21ras with phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A. 1991;88(18):7908–12.CrossRefGoogle Scholar
  21. 21.
    Currie RA, et al. Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1. Biochem J. 1999;337(Pt 3):575–83.CrossRefGoogle Scholar
  22. 22.
    Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296(5573):1655–7.CrossRefGoogle Scholar
  23. 23.
    Abe K, et al. Vav2 is an activator of Cdc42, Rac1, and RhoA. J Biol Chem. 2000;275(14):10141–9.CrossRefGoogle Scholar
  24. 24.
    Itoh RE, et al. Phosphorylation and activation of the Rac1 and Cdc42 GEF Asef in A431 cells stimulated by EGF. J Cell Sci. 2008;121(16):2635.CrossRefGoogle Scholar
  25. 25.
    Nobes CD, Hall A. Rho, Rac, and Cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell. 1995;81(1):53–62.CrossRefGoogle Scholar
  26. 26.
    Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279(5350):509–14.CrossRefGoogle Scholar
  27. 27.
    Watanabe N, et al. Cooperation between mDia1 and ROCK in rho-induced actin reorganization. Nat Cell Biol. 1999;1(3):136–43.CrossRefGoogle Scholar
  28. 28.
    Schlessinger K, Hall A, Tolwinski N. Wnt signaling pathways meet rho GTPases. Genes Dev. 2009;23(3):265–77.CrossRefGoogle Scholar
  29. 29.
    Fernandez-Zapico ME, et al. Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell. 2005;7(1):39–49.CrossRefGoogle Scholar
  30. 30.
    Caparello C, et al. FOLFIRINOX and translational studies: towards personalized therapy in pancreatic cancer. World J Gastroenterol. 2016;22(31):6987–7005.CrossRefGoogle Scholar
  31. 31.
    Chiorean EG, et al. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. Br J Cancer. 2016;115(2):188–94.CrossRefGoogle Scholar
  32. 32.
    Burris H, Storniolo AM. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer. 1997;33(Suppl 1):S18–22.CrossRefGoogle Scholar
  33. 33.
    Rivera F, et al. Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev. 2009;35(4):335–9.CrossRefGoogle Scholar
  34. 34.
    Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358(11):1160–74.CrossRefGoogle Scholar
  35. 35.
    Moore MJ, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960–6.CrossRefGoogle Scholar
  36. 36.
    Aranda E, et al. Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study). Ann Oncol. 2012;23(7):1919–25.CrossRefGoogle Scholar
  37. 37.
    Van Cutsem E, et al. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study. Br J Cancer. 2014;111(11):2067–75.CrossRefGoogle Scholar
  38. 38.
    Wang JP, et al. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget. 2015;6(20):18162–73.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Mosquera C, Maglic D, Zervos EE. Molecular targeted therapy for pancreatic adenocarcinoma: a review of completed and ongoing late phase clinical trials. Cancer Genet. 2016;209(12):567–81.CrossRefGoogle Scholar
  40. 40.
    Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors[mdash]impact on future treatment strategies. Nat Rev Clin Oncol. 2010;7(9):493–507.CrossRefGoogle Scholar
  41. 41.
    Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer. 2013;13(9):663–73.CrossRefGoogle Scholar
  42. 42.
    Arteaga CL, Engelman JA, Receptors ERBB. From oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25(3):282–303.CrossRefGoogle Scholar
  43. 43.
    Kimura K, et al. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin Cancer Res. 2006;12(16):4925.CrossRefGoogle Scholar
  44. 44.
    Harder J, et al. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br J Cancer. 2012;106(6):1033–8.CrossRefGoogle Scholar
  45. 45.
    Wu Z, et al. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2015;76(6):1309–14.CrossRefGoogle Scholar
  46. 46.
    Joshi M, Rizvi SM, Belani CP. Afatinib for the treatment of metastatic non-small cell lung cancer. Cancer Manag Res. 2015;7:75–82.CrossRefGoogle Scholar
  47. 47.
    Yu HA, Pao W. Targeted therapies: afatinib – new therapy option for EGFR-mutant lung cancer. Nat Rev Clin Oncol. 2013;10(10):551–2.CrossRefGoogle Scholar
  48. 48.
    Huguet F, et al. Afatinib, an irreversible EGFR family inhibitor, shows activity toward pancreatic cancer cells, alone and in combination with radiotherapy, independent of KRAS status. Target Oncol. 2016;11(3):371–81.CrossRefGoogle Scholar
  49. 49.
    Zhang H, et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest. 2007;117(8):2051–8.CrossRefGoogle Scholar
  50. 50.
    Takezawa K, et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR mutant lung cancers that lack the second-site EGFR T790M mutation. Cancer Discov. 2012;2(10):922–33.CrossRefGoogle Scholar
  51. 51.
    Larbouret C, et al. Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. Ann Oncol. 2010;21(1):98–103.CrossRefGoogle Scholar
  52. 52.
    Assenat E, et al. Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial. Oncotarget. 2015;6(14):12796–808.CrossRefGoogle Scholar
  53. 53.
    Bennouna J, Moreno Vera SR. Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress. Future Oncol. 2015;12(3):355–72.CrossRefGoogle Scholar
  54. 54.
    Chung KY, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005;23(9):1803–10.CrossRefGoogle Scholar
  55. 55.
    Bonine-Summers AR, et al. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biol Ther. 2007;6(4):561–70.CrossRefGoogle Scholar
  56. 56.
    Jo M, et al. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem. 2000;275(12):8806–11.CrossRefGoogle Scholar
  57. 57.
    Velpula KK, et al. EGFR and c-Met cross talk in glioblastoma and its regulation by human cord blood stem cells. Transl Oncol. 2012;5(5):379–IN18.CrossRefGoogle Scholar
  58. 58.
    Liska D, et al. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res. 2011;17(3):472.CrossRefGoogle Scholar
  59. 59.
    Corso S, et al. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer. 2010;9(1):121.CrossRefGoogle Scholar
  60. 60.
    Riedemann J, et al. The EGF receptor interacts with the type 1 IGF receptor and regulates its stability. Biochem Biophys Res Commun. 2007;355(3):707–14.CrossRefGoogle Scholar
  61. 61.
    Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 2002;62(1):200.PubMedGoogle Scholar
  62. 62.
    Truty MJ, Urrutia R. Basics of TGF-ß and pancreatic cancer. Pancreatology. 2007;7(5):423–35.CrossRefGoogle Scholar
  63. 63.
    Zhang YE. Non-Smad pathways in TGF-[beta] signaling. Cell Res. 2009;19(1):128–39.CrossRefGoogle Scholar
  64. 64.
    Ellenrieder V. TGFβ-regulated gene expression by Smads and Sp1/KLF-like transcription factors in cancer. Anticancer Res. 2008;28(3A):1531–9.PubMedGoogle Scholar
  65. 65.
    Seton-Rogers SE, et al. Cooperation of the ErbB2 receptor and transforming growth factor β in induction of migration and invasion in mammary epithelial cells. Proc Natl Acad Sci U S A. 2004;101(5):1257–62.CrossRefGoogle Scholar
  66. 66.
    Muraoka RS, et al. Increased malignancy of neu-induced mammary tumors overexpressing active transforming growth factor β1. Mol Cell Biol. 2003;23(23):8691–703.CrossRefGoogle Scholar
  67. 67.
    Muraoka-Cook RS, et al. Activated type I TGF[beta] receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene. 2005;25(24):3408–23.CrossRefGoogle Scholar
  68. 68.
    Ueda Y, et al. Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor β-induced cell motility. J Biol Chem. 2004;279(23):24505–13.CrossRefGoogle Scholar
  69. 69.
    Deharvengt S, Marmarelis M, Korc M. Concomitant targeting of EGF receptor, TGF-beta and Src points to a novel therapeutic approach in pancreatic cancer. PLoS One. 2012;7(6):e39684.CrossRefGoogle Scholar
  70. 70.
    Fernández-Zapico ME. Primers on molecular pathways GLI: more than just hedgehog? Pancreatology. 2008;8(3):227–9.CrossRefGoogle Scholar
  71. 71.
    Schnidar H, et al. Epidermal growth factor receptor signaling synergizes with hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway. Cancer Res. 2009;69(4):1284.CrossRefGoogle Scholar
  72. 72.
    Eberl M, et al. Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells. EMBO Mol Med. 2012;4(3):218.CrossRefGoogle Scholar
  73. 73.
    Götschel F, et al. Synergism between hedgehog-GLI and EGFR signaling in hedgehog-responsive human medulloblastoma cells induces downregulation of canonical hedgehog-target genes and stabilized expression of GLI1. PLoS One. 2013;8(6):e65403.CrossRefGoogle Scholar
  74. 74.
    Heo JS, Lee MY, Han HJ. Sonic hedgehog stimulates mouse embryonic stem cell proliferation by cooperation of Ca2+/protein kinase C and epidermal growth factor receptor as well as Gli1 activation. Stem Cells. 2007;25(12):3069–80.CrossRefGoogle Scholar
  75. 75.
    Whisenant TC, et al. Computational prediction and experimental verification of new MAP kinase docking sites and substrates including gli transcription factors. PLoS Comput Biol. 2010;6(8):e1000908.CrossRefGoogle Scholar
  76. 76.
    Pasca di Magliano M, et al. Hedgehog/Ras interactions regulate early stages of pancreatic cancer. Genes Dev. 2006;20(22):3161–73.CrossRefGoogle Scholar
  77. 77.
    Hu W-G, et al. Blockade of sonic hedgehog signal pathway enhances antiproliferative effect of EGFR inhibitor in pancreatic cancer cells. Acta Pharmacol Sin. 2007;28(8):1224–30.CrossRefGoogle Scholar
  78. 78.
    Civenni G, Holbro T, Hynes NE. Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells. EMBO Rep. 2003;4(2):166.CrossRefGoogle Scholar
  79. 79.
    Krejci P, et al. Receptor tyrosine kinases activate canonical WNT/β-catenin signaling via MAP kinase/LRP6 pathway and direct β-catenin phosphorylation. PLoS One. 2012;7(4):e35826.CrossRefGoogle Scholar
  80. 80.
    Lu Z, et al. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of β-catenin, and enhanced tumor cell invasion. Cancer Cell. 2003;4(6):499–515.CrossRefGoogle Scholar
  81. 81.
    Avila JL, Kissil JL. Notch signaling in pancreatic cancer: oncogene or tumor suppressor? Trends Mol Med. 2013;19(5):320–7.CrossRefGoogle Scholar
  82. 82.
    Dong Y, et al. Synthetic lethality through combined notch–epidermal growth factor receptor pathway inhibition in basal-like breast cancer. Cancer Res. 2010;70(13):5465.CrossRefGoogle Scholar
  83. 83.
    Miyamoto Y, et al. Notch mediates TGFbeta-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell. 2003;3(6):565–76.CrossRefGoogle Scholar
  84. 84.
    De La O J-P, et al. Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci. 2008;105(48):18907–12.CrossRefGoogle Scholar
  85. 85.
    Hanlon L, et al. Notch1 functions as a tumor suppressor in a model of K-ras–induced pancreatic ductal adenocarcinoma. Cancer Res. 2010;70(11):4280.CrossRefGoogle Scholar
  86. 86.
    DeCant BT, et al. Utilizing past and present mouse systems to engineer more relevant pancreatic cancer models. Front Physiol. 2014;5:464.CrossRefGoogle Scholar
  87. 87.
    Wang Z. Transactivation of epidermal growth factor receptor by G protein-coupled receptors: recent progress, challenges and future research. Int J Mol Sci. 2016;17(1):95.CrossRefGoogle Scholar
  88. 88.
    Fredriksson R, et al. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol. 2003;63(6):1256.CrossRefGoogle Scholar
  89. 89.
    Gutkind JS. The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades. J Biol Chem. 1998;273(4):1839–42.CrossRefGoogle Scholar
  90. 90.
    Lappano R, Maggiolini M. GPCRs and cancer. Acta Pharmacol Sin. 2012;33(3):351–62.CrossRefGoogle Scholar
  91. 91.
    Dabrowski A, et al. Cholecystokinin and EGF activate a MAPK cascade by different mechanisms in rat pancreatic acinar cells. Am J Physiol Cell Physiol. 1997;273(5):C1472.CrossRefGoogle Scholar
  92. 92.
    Smith JP, Fonkoua LK, Moody TW. The role of gastrin and CCK receptors in pancreatic cancer and other malignancies. Int J Biol Sci. 2016;12(3):283–91.CrossRefGoogle Scholar
  93. 93.
    Navas C, et al. EGF receptor signaling is essential for K-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell. 2012;22(3):318–30.CrossRefGoogle Scholar
  94. 94.
    Smith JP, et al. Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in Mice. Pancreas. 2014;43(7):1050–9.CrossRefGoogle Scholar
  95. 95.
    Ryder NM, et al. G protein–coupled receptor signaling in human ductal pancreatic cancer cells: neurotensin responsiveness and mitogenic stimulation. J Cell Physiol. 2001;186(1):53–64.CrossRefGoogle Scholar
  96. 96.
    Mishani E, et al. Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. Curr Pharm Des. 2008;14(28):2983–98.CrossRefGoogle Scholar
  97. 97.
    Saccomano M, et al. Preclinical evaluation of near-infrared (NIR) fluorescently labeled cetuximab as a potential tool for fluorescence-guided surgery. Int J Cancer. 2016;139(10):2277–89.CrossRefGoogle Scholar
  98. 98.
    Nielsen CH, et al. In vivo imaging of therapy response to a novel Pan-HER antibody mixture using FDG and FLT positron emission tomography. Oncotarget. 2015;6(35):37486–99.CrossRefGoogle Scholar
  99. 99.
    England CG, et al. Molecular imaging of pancreatic cancer with antibodies. Mol Pharm. 2016;13(1):8–24.CrossRefGoogle Scholar
  100. 100.
    Ricono JM, et al. Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. Cancer Res. 2009;69(4):1383–91.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Laboratory of Epigenetics and Chromatin Dynamics, Gastroenterology Research Unit, Division of Gastroenterology and Hepatology, Department of MedicineMayo ClinicRochesterUSA
  2. 2.Division of Research, Department of SurgeryMedical College of WisconsinMilwaukeeUSA
  3. 3.Division of Research, Department of Surgery and Genomic Sciences and Precision Medicine Center (GSPMC)Medical College of WisconsinMilwaukeeUSA

Section editors and affiliations

  • Raul A. Urrutia
    • 1
  • Markus W. Büchler
    • 2
  • John Neoptolemos
    • 3
  • Thilo Hackert
    • 4
  1. 1.Mayo Clinic Cancer CenterMayo ClinicRochesterUSA
  2. 2.Department of General, Visceral and Transplantation SurgeryUniversity of HeidelbergHeidelbergGermany
  3. 3.Division of Surgery and OncologyUniversity of LiverpoolLiverpoolUK
  4. 4.Department of General, Visceral and Transplantation SurgeryUniversity of HeidelbergHeidelbergGermany

Personalised recommendations